Author: Ron Shinkman

Gilead’s HIV Drug Reimbursement Cut Will be Devastating, 340B Covered Entities Say

In Pharma IndustryApril 13, 2021

Drug manufacturer Gilead late last week announced a huge cut, effective Jan. 1, 2022, in pharmacy reimbursement for its HIV and hepatitis B medicines that uninsured individuals get for free through Gilead’s Advancing Access patient assistance program (PAP). 340B HIV/AIDS …

NY State 340B Providers Get More Time to Challenge Reimbursement Change

In Legislative, StateApril 8, 2021

Ron Shinkman

New York state lawmakers and Gov. Andrew Cuomo (D) agreed this week to postpone transferring Medicaid managed care prescription drug benefits to Medicaid fee for service (FFS) for two years, temporarily averting a significant financial loss to 340B covered entities. …

Panel Lauds Women’s Role in Creating and Leading 340B

In Trade AssociationApril 6, 2021

Ron Shinkman

Women have played a key role in the 340B program since its inception nearly 30 years ago. Their historic and ongoing involvement was observed and celebrated in “Notable Women of 340B,” a webinar broadcast by Community Voices for 340B (CV-340B) …

Panelists Share Insights on Using 340B in Prisons and Jails

In Federal, RegulatoryApril 1, 2021

Ron Shinkman

Prisons struggling with the high cost of treating inmates with viral illnesses such as hepatitis C and HIV can turn to the 340B program for relief, but participation is often tricky.

Please Login or Become a

…

340B Entities Keeping Watch on Bills to Create State Drug Affordability Boards

In Regulatory, StateMarch 30, 2021

Ron Shinkman

Nine states are considering legislation to create boards to review prescription drug prices and intervene to lower them if drugs become too expensive or if their prices spike. Although the board’s implications for the 340B program have not been fully …

340B Gets Cameo Role in Senate Hearing on Government Drug Price Negotiation

In Federal, LegislativeMarch 25, 2021

Ron Shinkman

The Senate committee with direct jurisdiction over the 340B program held its first drug pricing hearing of the 117th Congress Tuesday. It held the session amid signs that House Democrats want to add language to let Medicare negotiate drug prices …

Survey: Pharma’s 340B Contract Pharmacy Actions are Putting the Squeeze on Hospitals

In Research/Reports, Trade AssociationMarch 23, 2021

Ron Shinkman

340B hospitals are under significant pressure due to drug manufacturers ending 340B discounts on drugs dispensed by contract pharmacies, hospital advocacy group 340B Health says in its latest annual member survey.

Please Login or Become a

…

Becerra Expected To Usher in Sea Change to 340B Governance

In Federal, LegislativeMarch 18, 2021

Ron Shinkman

After what initially appeared to be a rocky path to confirmation and a deadlocked vote in the U.S. Senate Finance Committee, current California Attorney General Xavier Becerra (D) is widely expected to be confirmed today, shortly after noon Eastern, as …

FQHCs Fiercely Oppose Trump’s 340B Insulin Pricing Rule in New Round of Comments

In Federal, RegulatoryMarch 16, 2021

Ron Shinkman

Federally qualified health centers and their trade groups are adamantly opposed to implementing a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under …

State Activity to Rein in PBM Discrimination Against 340B Entities Heats Up

In Regulatory, StateMarch 11, 2021

Ron Shinkman

At least six states have introduced or passed bills in recent weeks that would forbid pharmacy benefit managers from discriminating against 340B covered entities regarding reimbursements and other practices.

Please Login or Become a Paid Subscriber

…